Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23336
Title: Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Authors: Lim, Bryant;Li, Qiao-Xin;Rowe, Christopher C;Dhiman, Kunal;Gupta, Veer Bala;Masters, Colin L;Doecke, James D;Martins, Ralph N;Collins, Steven;Diamandis, Eleftherios P
Affiliation: School of Medicine, Deakin University, VIC, Australia
Department of Clinical Biochemistry, University Health Network, Toronto, Canada
Florey Institute, University of Melbourne, Parkville, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Heidelberg, Australia
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
Centre of Excellence in Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, Australia
The Australian eHealth Research Centre, CSIRO, Brisbane, Queensland, Australia
Issue Date: 22-May-2020
EDate: 2020-05-22
Citation: Neuroscience letters 2020: 135078
Abstract: Multifactorial pathological processes of Alzheimer's disease (AD) begin decades prior to clinical onset. Early identification of patients at risk of developing AD using biomarkers reflecting various aspects of pathogenesis is necessary for prevention and early intervention. Cortical β-amyloid (Aβ) burden assessed by positron emission tomography (PET) or cerebrospinal fluid (CSF) levels of Aβ42 are validated biomarkers for early identification. Recently, alterations in levels of neuronal proteins, neuronal pentraxin receptor (NPTXR) and neurofilament light (NfL), in the CSF have emerged as promising AD biomarkers. However, their association with Aβ deposition is not well understood. In this pilot study, we evaluate whether CSF NfL and NPTXR are associated with PET-Aβ imaging and core CSF biomarkers (Aβ42, T-tau, and P-tau). CSF samples were collected from a sub-cohort of participants from the Australian Imaging Biomarkers and Lifestyle study of aging (AIBL) and categorized as either PET-Aβ positive (n = 15) or negative (n = 15). NPTXR was significantly lower in PET-Aβ positive than negative individuals (p =  0.04), and correlated with Aβ42 (rho = 0.69, p <  0.0001), T-tau (rho = 0.45, p =  0.01), and P-tau (rho = 0.51, p =  0.004). However, CSF NfL was not significantly different between PET-Aβ positive and negative individuals and did not correlate with any of the core CSF biomarkers. Similar associations of NPTXR and the core CSF biomarkers persisted in the cognitively normal individuals. Together, NPTXR concentration in CSF may be more sensitive NfL to identify AD risk during the preclinical stage, warranting further investigation into its contribution to AD pathogenesis.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23336
DOI: 10.1016/j.neulet.2020.135078
ORCID: 0000-0003-3910-2453
PubMed URL: 32450185
Type: Journal Article
Subjects: Alzheimer’s disease
Aβ-amyloid
cerebrospinal fluid
neurofilament light
neuronal pentraxin receptor
positron emission tomography
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.